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Background. Murine typhus, or infection with Rickettsia typhi, is a global but neglected disease without randomized clinical 
trials to guide antibiotic therapy. 
Methods. A prospective, open, randomized trial was conducted in nonpregnant, consenting inpatient adults with rapid diagnos-
tic test evidence of uncomplicated murine typhus at 2 hospitals in Vientiane, Laos. Patients were randomized to 7 days (D7) or 3 days 
(D3) of oral doxycycline or 3 days of oral azithromycin (A3). Primary outcome measures were fever clearance time and frequencies 
of treatment failure and relapse. 
Results. Between 2004 and 2009, the study enrolled 216 patients (72 per arm); 158 (73.2%) had serology/polymerase chain 
reaction (PCR)–confirmed murine typhus, and 52 (24.1%) were R. typhi PCR positive. The risk of treatment failure was greater for 
regimen A3 (22.5%; 16 of 71 patients) than for D3 (4.2%; 3 of 71) or D7 (1.4%; 1 of 71) (P < .001). Among R. typhi PCR–positive 
patients, the area under the time-temperature curve and the fever clearance time were significantly higher for A3 than for D3 (1.8- 
and 1.9-fold higher, respectively; P = .005) and D7 (1.5- and 1.6-fold higher; P = .02). No patients returned with PCR-confirmed 
R. typhi relapse.
Conclusion. In Lao adults, azithromycin is inferior to doxycycline as oral therapy for uncomplicated murine typhus. For dox-
ycycline, 3- and 7-day regimens have similar efficacy. Azithromycin use in murine typhus should be reconsidered. Investigation of 
genomic and phenotypic markers of R. typhi azithromycin resistance is needed.
Clinical Trial Registration. ISRCTN47812566.
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Murine typhus, caused by Rickettsia typhi, is a neglected global 
flea-borne disease with sparse worldwide data on epidemiol-
ogy and no randomized clinical trials to guide therapy [1, 2]. 
Although most commonly a febrile illness with few localizing 
signs, it also causes severe disease, such as meningoencephalitis 
and pneumonitis [3]. The diagnosis of R. typhi infection is dif-
ficult, resembling many other causes of fever, but recent reports 
highlight its global importance [1–6]. R.  typhi is in the same 
antigenic group as Rickettsia prowazekii, the cause of epidemic 
typhus and a more severe disease [6].
Tetracyclines are the mainstays of treatment, but there is 
minimal evidence on optimal duration or how to treat in preg-
nancy, childhood, or severe disease [1, 2, 4, 6, 7]. A 5–10-day 
chloramphenicol course or a single 200-mg oral doxycycline 
dose resulted in defervescence within 2  days in about 70% 
of Thai patients with murine typhus [8]. A  review of Cretan 
patients with murine typhus suggested that doxycycline was 
associated with a shorter fever clearance time (FCT) than chlor-
amphenicol or fluoroquinolones [9]. The clinical efficacy of flu-
oroquinolones is in doubt [10–12], with equivocal evidence for 
azithromycin [13, 14].
R.  typhi antibiotic susceptibility testing cannot be assessed 
by conventional techniques. The few genotypic and phenotypic 
susceptibility data available suggest that R. typhi is susceptible 
to tetracyclines, chloramphenicol, azithromycin, erythromycin, 
clarithromycin, and fluoroquinolones and resistant to amoxicillin, 
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cotrimoxazole, and gentamicin [6, 7, 15–17]. Resistance to 
rifampin has been described, associated with rpoB gene point 
mutations [18]. Azithromycin has been shown to be efficacious 
by means of in vitro assays against diverse Rickettsia species [19]. 
We therefore conducted a randomized open-label clinical trial 
to provide evidence for the optimum duration of treatment of 
murine typhus in Laos and to test azithromycin as an alterna-
tive therapy.
PATIENTS AND METHODS
Study Design
An open, randomized, superiority trial was performed in adults 
with rapid diagnostic test (RDT) evidence of infection with 
uncomplicated murine typhus, to compare the therapeutic effi-
cacy of 3 oral treatment regimens: 7 days of doxycycline (D7), 
3 days of doxycycline (D3), and 3 days of azithromycin (A3). 
The study was conducted at 2 primary-tertiary care hospitals 
in Vientiane: Mahosot Hospital (400 beds) and Sethathirat 
Hospital (200 beds). Ethical clearance was granted by the 
Ethical Review Committee of the Faculty of Medical Sciences, 
National University of Laos, Vientiane, and the Oxford Tropical 
Research Ethics Committee in the United Kingdom.
Eligible participants admitted to the infectious disease wards 
at both hospitals were screened and enrolled by study physi-
cians. Nonpregnant adults (aged ≥15  years) admitted with 
suspected uncomplicated typhus were included in the study 
providing they had a positive anti–R.  typhi immunoglobulin 
M (IgM) result, were able to take oral medication, gave writ-
ten informed consent, and had a high likelihood of remaining 
in the hospital for the duration of treatment and completing 
≥4 weeks of follow-up. A negative urinary pregnancy test was 
required for women of childbearing age. 
Exclusion criteria included known administration of chlo-
ramphenicol, doxycycline, tetracycline, fluoroquinolones, or 
azithromycin during the week before admission; pregnancy 
or breastfeeding; and hypersensitivity or contraindications to 
doxycycline (severe hepatic impairment, known systemic lupus 
erythematosus) or azithromycin (severe hepatic impairment). 
Patients were also excluded if they had evidence of another 
cause of fever or severe disease, defined as ≥1 of the following: 
reduced level of consciousness, jaundice, systolic blood pressure 
<80 mm Hg, vomiting, respiratory distress (respirations, >30/
min), or any other syndrome that in the opinion of the admit-
ting physician constituted severe typhus. Patients were not 
involved in the design of this trial. (Clinical trial registration: 
ISRCTN47812566.)
Randomization
Patients were randomized to 3 groups: (1) D7, doxycycline 
with a 200-mg loading dose, followed by 100  mg every 12 
hours for 7  days; (2) D3, doxycycline with a 200-mg loading 
dose, followed by 100 mg every 12 hours for 3 days; or (3) A3, 
azithromycin with a 500-mg loading dose, followed by 250 mg 
every 24 hours for 2 days.
The drugs used were doxycycline hyclate (Vibramycin, 
100-mg film-coated tablets; Pfizer) and azithromycin dihy-
drate (Zithromax, 250-mg capsules; Pfizer). Randomization, 
in blocks of 12, was computer generated by an investigator not 
involved in patient recruitment. Treatment allocations were 
kept in sealed opaque envelopes and opened, by recruiting 
study physicians, when all inclusion and exclusion criteria were 
checked and consent forms signed. Paracetamol was given for 
fever as needed by the patient and antacids avoided. The inges-
tion of all study drugs was witnessed by the ward nursing staff. 
If a patient vomited within 1 hour after drug ingestion, the full 
dose was repeated.
Procedures
All consenting patients with a history of fever and suspected 
typhus had venous blood taken and aliquoted for serum (3 mL) 
and whole blood in ethylenediaminetetraacetic acid (EDTA) 
(5 mL) for a full blood count (Abx Micros 60; Abx Hematologie) 
and 2 blood cultures (5  mL in a 50-mL blood culture bottle) 
that were incubated in air at 37°C for 7 days (Table 1). Bacteria 
isolated from blood cultures were identified using standard bio-
chemical tests and specific antisera. If the patient came from an 
area with endemic malaria, Giemsa-stained malaria thick and 
thin films were examined. 
Samples were stored at −80°C until analysis and transported 
on dry ice. IgM antibodies to murine typhus were screened 
by the Dip-S-Ticks Murine typhus (D-RTY03T, PanBio, now 
GenBio, adapted by detecting IgM). These have a sensitivity 
and specificity for diagnosing murine typhus of 61% and 87%, 
respectively, compared with indirect immunofluorescence 
assays (IFAs) [20]. IgM and immunoglobulin G (IgG) anti-
bodies against R. typhi were detected using IFA after the study 
was completed, using slides coated with R.  typhi Wilmington 
antigen (Australian Rickettsial Reference Laboratory). Patient 
serum samples were serially 2-fold diluted from 1:400 to 1:3200, 
and the end point was determined as the highest titer displaying 
specific fluorescence. Positivity was defined as (1) ≥4-fold rising 
titer in IgM or IgG antibodies when comparing admission with 
subsequent longitudinal samples and/or (2) a positive recipro-
cal titer of ≥3200 in an admission sample.
EDTA buffy coat samples underwent genomic DNA 
extraction using the QIAmp DNA Mini Kit (Qiagen), followed 
by detection of the 47-kDa htrA gene of Orientia tsutsugamushi, 
17-kDa gene of Rickettsia spp., and the rrs gene of Leptospira 
spp. (see Supplementary Material for details).
Patients’ admission clinical history and examination were 
recorded using standard questionnaires and reviewed daily. 
Tympanic temperature was recorded every 6 hours, using 
tympanic thermometers (Genius; Tyco Healthcare). For those 
Mahosot Hospital patients who consented, follow-up was 
740 • CID 2019:68 (1 March) • Newton et al
conducted on days 14 and 28 and at 3, 6, and 12 months, with 
repeated venous blood collection. Patients were encouraged to 
return if they felt unwell within the year after discharge.
Outcomes
The primary outcome measures were FCT, and frequencies of 
treatment failure and confirmed relapse with, as secondary out-
come, area under the time-temperature curve (AUC). FCT was 
defined as the time, from onset of treatment, to the first time 
tympanic temperature dropped below 37.5°C, after a rise to 
≥37.5°C, and remained at ≤37.5°C for 24 hours. FCT spanned 
primary and rescue therapy for those with treatment failure, 
which was defined as fever >37.5°C after ≥72 hours of the 
assigned treatment without clinical improvement or with devel-
opment of severe disease. Patients in whom first-line treatments 
failed were treated with 7 days doxycycline (100 mg every 12 
hours with loading dose, as described above). Detailed clini-
cal history, examination, and investigations were performed to 
determine the cause of fever in those with apparent “relapse.” 
Confirmed relapse was defined as a patient presenting again 
with fever and R.  typhi buffy coat polymerase chain reaction 
(PCR) positivity because it was not possible to reliably clinically 
Table 1. Clinical and Laboratory Features of Patients Recruited to Murine Typhus Clinical Trial
Variablea All Patients
Rickettsia typhi Positive
Serology and/or PCR PCR 
Patients, No. (%) 216 (100) 158 (73.2)b 52 (24.2)c
Age, median (IQR), y 30 (22–41) 30 (21–42) 39 (22–47)
Female sex, No. (%) 91 (42.1) 61 (38.6) 20 (38.5)
Duration of illness, median (IQR), d 8 (7–10) 8 (7–10) 8 (7–10)
Symptoms, No. (%)
 Headache 204/215d (94.9) 152/157 (96.8) 51 (98.1)
 Myalgia 164 (75.9) 122 (77.2) 45 (86.5)
 Abdominal pain 15/215 (7.0) 12/157 (7.6) 6 (11.5)
 Nausea 63 (29.2) 48 (30.4) 16 (30.8)
 Vomiting 60 (27.8) 45 (28.5) 16 (30.8)
 Diarrhea 58 (26.9) 44 (27.9) 21 (40.4)
 Cough 97 (44.9) 69 (43.7) 24 (46.2)
 Lymphadenopathy 28/215 (13.0) 21/157 (13.4) 9 (17.3)
 Rash 41 (19.0) 31 (19.6) 14 (26.9)
 Liver palpable 19 (8.8) 12 (7.6) 4 (7.7)
 Spleen palpable 13 (6.0) 10 (6.3) 4 (7.7)
Tympanic temperature, mean (95% CI), °C 38.5 (38.4–38.7) 38.6 (38.4–38.7) 38.7 (38.5–38.9)
Pulse rate, median (IQR), pulses/min 98 (88–100) (n = 215)d 98 (88–100) (n = 157) 100 (89–100)
Systolic BP, median (IQR), mm Hg 100 (100–120) 100 (100–120) 100 (95–120)
Diastolic BP, median (IQR), mm Hg 70 (60–80) 70 (60–80) 70 (60–80)
Respiratory rate, mean (95% CI), respirations/min 22.3 (21.5–23.0) (n = 213) 22.3 (21.3–23.4) (n = 155) 22.4 (21.4–23.4)
Body weight, mean (95% CI), kg 54.6 (53.2–55.9) 55.7 (54.1–57.2) 57.4 (54.5–60.3)
Hematocrit, mean (95% CI), % 40.6 (39.9–41.4) (n = 215) 40.7 (39.8–41.7) (n = 157) 40.1 (38.6–41.6) (n = 51)
WBC count, median (IQR), 109/L 8.3 (6.4–10.3) (n = 214) 7.9 (6.4–9.9) (n = 156) 7.8 (5.8–9.9) (n = 51)
Neutrophils, mean (95% CI), % 64.8 (63.2–66.4) (n = 215) 64.3 (62.7–65.9) (n = 157) 66.0 (63.0–69.0) (n = 51)
Platelet count, mean (95% CI), 109/L 192 (185–199) (n = 213) 191 (183–200) (n = 155) 187 (169–205) (n = 51)
Serum CRP, median (IQR), mg/L 37.6 (18.5–83.3) (n = 197) 34.9 (18.5–76.0) (n = 147) 66.9 (21.9–111.9) (n = 49)
Serum creatinine, median (IQR), μmol/L 97 (80–106) (n = 205) 97 (80–106) (n = 153) 97 (80–115)
Serum AST, median (IQR), IU/L 91 (50–165) (n = 200) 101 (58–167) (n = 149) 141 (84–187) (n = 49)
Serum ALT, median (IQR), IU/L 33 (18–61) (n = 197) 36 (22–69) (n = 147) 42 (27–71) (n = 49)
Serum albumin, median (IQR), g/L 3.6 (3.2–4.0) (n = 202) 3.6 (3.2–4.0) (n = 151) 3.2 (2.8–3.6) (n = 51)
Serum alkaline phosphatase, median (IQR), IU/L 105 (74–168) (n = 199) 119 (77–182) (n = 149) 168 (96–260) (n = 49)
Serum total bilirubin, median (IQR), μmol/L 5.1 (5.1–8.6) (n = 198) 5.1 (5.1–8.6) (n = 147) 6.8 (5.1–13.7) (n = 49)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; CRP, C-reactive protein; IQR, interquartile range; PCR, polymerase chain reaction; WBC, 
white blood cell.
aReference ranges for laboratory values were as follows: WBC count, 4.0–11.0 109/L; platelet count, 150–400 109/L; serum CRP, <10 mg/L; serum creatinine, 53–123 μmol/L; serum AST, 7–40 
IU/L; serum ALT, 7–40 IU/L; serum albumin, 3.5–5.0 g/L; serum alkaline phosphatase 24–190 IU/L; and serum total bilirubin, 1.7–20 μmol/L.
bA total of 163 patients had serologic or PCR evidence of R. typhi infection, but 5 had PCR/culture evidence of another pathogen (Escherichia coli, Salmonella Typhi, Leptospira spp. in 1 each 
and Orientia tsutsugamushi in 2). They may have had concurrent dual infections, but we have opted to be conservative and not included these 5 patients, giving a denominator of 158 patients
cA total of 53 patients had PCR evidence of R. typhi infection, but 1 patient was also PCR positive for Leptospira spp., with an apparent dual concurrent infection, and is thus excluded from 
this column.
dDenominators are provided for variables with missing values.
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distinguish R.  typhi relapse from other causes of fever, and 
serology responses in R. typhi relapse are not known.
Statistical Analysis
Without local data on murine typhus FCT and treatment fail-
ure, sample size calculations were performed at interim analysis 
after 51 patients; there were no failures in the D7 group (0 of 18 
patients), a 12.5% failure rate (2 of 16 patients) in the D3 group, 
and a 29.4% failure rate (5 of 17) in the A3 group. To detect a 
significant difference in the proportion of failures between the 
reference group (using 0.1%) and the D3 group, a sample size of 
67 per group provided 80% power and an α value of .05, with 
sufficient power to detect a difference between the D7 and A3 
groups as well. To account for potential patient withdrawal, 72 
patients per group were recruited (n = 216 total).
Outcomes were compared across the 3 treatment groups 
and also by subgroups: serology- or PCR-confirmed R. typhi 
(single infection) and PCR-confirmed R.  typhi. We regarded 
PCR positivity as a method with higher specificity to diagnose 
R.  typhi than serology. Frequencies were reported as num-
bers and percentages and analyzed using χ2 test. Risks were 
quantified using logistic regression and treatment allocation 
as a categorical covariate, with D7 serving as the referent 
group. Median FCTs were estimated using survival analysis 
and plotted using Kaplan-Meier curves. The survival func-
tions were compared using the log-rank test. AUC was calcu-
lated using the trapezoid rule to the time when temperature 
dropped below 37.5°C and stayed at ≤37.5°C for ≥24 hours. 
For patients whose fever did not clear, the time of discharge 
was used. Patients who were afebrile (and stayed afebrile) at 
admission were excluded from the AUC analysis. AUCs were 
compared between the 3 treatment groups using the Kruskal-
Wallis test. Analysis was performed using Stata software (ver-
sion 14.2; StataCorp).
RESULTS
Between 21 March 2004 and 13 August 2009, a total of 2313 and 
265 inpatients at Mahosot and Sethathirat Hospitals, respec-
tively, were screened using anti–R.  typhi IgM RDTs; 480 had 
murine typhus diagnosed, 416 (87%) at Mahosot Hospital and 
64 (13%) at Sethathirat (Figure 1). Two hundred sixteen patients 
(45%; 72 patients in each treatment group) were recruited into 
the trial (180 at Mahosot, 36 at Sethathirat Hospital); 91 (42%) 
were female, with a median age of 30 years (interquartile range 
[IQR], 22–41 years) (Table 1). The main reasons for exclusion 
(n = 264) were that patients were unlikely to be able to stay on 
the ward for 7  days and/or complete follow-up (95 patients; 
36.0%), had severe disease (50; 18.9%), had taken antirickettsial 
antibiotics (31; 11.7%), were not admitted to the study wards 
(27; 10.2%), declined consent (23; 8.7%), or were pregnant or 
breastfeeding (11; 4.2%) (Figure  1). Three patients, 1 in each 
treatment group, withdrew.
Patients were recruited in all months, with peaks in May–June 
(Figure 2). The trial ended when the target of 216 patients was 
enrolled. Most patients lived in Vientiane City (199 patients; 
92%) and Vientiane Province (15; 6.9%). The most common 
occupations were student (50 patients; 23.1%), trader (38; 
17.6%), construction worker (20; 9.3%), and government offi-
cial (19; 8.8%). Of 204 patients with data, 91 (45%) stated that 
they had taken antibiotics in the week before admission; none 
had taken an antibiotic known to be active against R. typhi.
Of the 216 patients, 158 (73.2%) had murine typhus con-
firmed by IFA and/or PCR, without evidence of dual infec-
tions, including 52 of 216 (24.1%) with PCR lone-infection 
evidence of R.  typhi. The median (IQR) bacterial load in 45 
R.  typhi PCR–positive patients was 3 (2–6) copies/μL whole 
blood (Tables 2 and 3).
Of 160 patients (74.1%) with IgM/IgG serologic evidence 
of R.  typhi infection, 5 had PCR/culture evidence of another 
pathogen (Escherichia coli, Salmonella enterica serovar Typhi, 
and Leptospira sp. in 1 each and O. tsutsugamushi in 2) (Tables 2 
and 3). These patients may have had concurrent genuine dual 
infections and were not included in the analysis.
Pathogens were identified by PCR for 62 patients (28.7%): 53 
with R. typhi, 6 with O. tsutsugamushi, and 4 with Leptospira spp. 
One patient was PCR positive for both R. typhi and Leptospira 
sp. Another 5 patients without IFA IgM and IgG evidence of 
R.  typhi were blood culture positive (4 with Salmonella Typhi 
and 1 with Salmonella Paratyphi A) (Table 2). At examination, 
3 patients (1.3%) had eschars; all were PCR positive for O. tsut-
sugamushi. Malaria films obtained in 183 patients (85%) were 
negative. Three patients with positive anti–R.  typhi IgM RDT 
and R. typhi PCR results had negative R. typhi IgM and IgG IFA 
results (see Patients and Methods).
Seventy-two patients were randomly assigned to each of the 
3 treatment groups (Table 3 and Figure 1). Of the 158 patients 
with confirmed single-pathogen murine typhus infection, 55 
(34.8%), 54 (34.2%), and 49 (31.0%) were included in the D7, 
D3, and A3 groups, respectively.
The mean total doxycycline doses were 27.5 (95% CI, 26.0–
29.0) and 14.0 (13.1–15.0) mg/kg body weight for D7 and D3 
patients, respectively. For the A3 group, the mean total azith-
romycin dose was 18.9 (95% CI, 18.1–19.6) mg/kg (Table  3). 
There were 17 protocol violations and 3 patients withdrew, 
not allowing classification for treatment failure (Figure  1 and 
Supplementary Material). Twelve of 192 patients (6.3%) with 
data vomited within 1 hour of the loading dose, 3.2% (2 of 
62)  in the A3 group and 7.7% (10 of 130)  in the D7 and D3 
groups combined (P = .34).
All patients survived to discharge. The median duration of hos-
pital admission was 8 days (IQR, 7–10 days; range, 2–90 days). 
Treatment failed in 20 (9.4%) of 213 patients (3 withdrew); 1 
of 71 (1.4%) in the D7 group, 3 of 71 (4.2%) in the D3 group, 
and 16 of 71 (22.5%) in the A3 group (P < .001; Table 4). The 
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risk of treatment failure (Table 4 and Supplementary Material) 
was also significantly higher in the A3 group than in the D7 
and D3 groups when only those with molecular and/or sero-
logically confirmed R. typhi (P = .001; n = 157) and those PCR 
positive for R. typhi (P = .002; n = 51) were considered. Those 
who failed treatment did not have only raised temperature 
but were also clinically unwell; none developed severe disease 
(Supplementary Material). The number of patients who cleared 
fever by 72 hours was also significantly lower in the A3 group 
for all patients (P = .001) and those R. typhi PCR and/or serol-
ogy positive (P = .001). The median (IQR) FCT was significantly 
longer in the A3 group, at 48 (IQR, 24–96) hours, compared 
Screened for murine typhus (n = 2578)
Excluded (n = 264)
Not meeting inclusion criteria (n = 235)
Declined to participate (n = 23)
Unrecorded reasons (n = 6)
Randomized (n = 216)
Doxycycline 7 days
(n = 72)
Received allocated 
intervention (n = 72)
A
llo
ca
tio
n
En
ro
llm
en
t
Azithromycin 3 days
(n = 72)
Received allocated 
intervention (n = 72)
Fo
llo
w
-u
p
Withdrew and lost to 
follow-up
(n = 1) 
Withdrew and lost to 
follow-up (n = 1)
A
na
ly
sis
Analyzed (n = 71)
Excluded from analysis of 
treatment failure frequency
(n = 1) (withdrew)
Analyzed (n = 71)
Excluded from analysis of 
treatment failure frequency
(n = 1) (withdrew), included 
in FCT calculation
Doxycycline 3 days
(n = 72)
Received allocated 
intervention (n = 72)
Withdrew and lost to 
follow-up (n = 1)
Analyzed (n = 71)
Excluded from analysis of 
treatment failure frequency
(n = 1) (withdrew), included 
in FCT calculation
Murine typhus confirmed 
= 55 (76.4%) 
Protocol violation = 8
Treatment failure = 1
Returned with fever = 7
Murine typhus 
confirmed = 54 (75.0%) 
Protocol violation = 11
Treatment failure = 3
Returned with fever = 9
Murine typhus
confirmed = 49 (68.1%) 
Protocol violation = 2
Treatment failure = 16
Returned with fever = 10
Murine typhus RDT positive (n = 480)
Figure 1. Flowchart of the clinical trial. Patients were excluded (n = 264) because they were unlikely to be able to stay on the ward for 7 days and/or complete follow-up 
(95 patients; 36.0%), had severe disease (50; 18.9%), had taken antirickettsial antibiotics (31; 11.7%), were not admitted to the study wards (27; 10.2%), declined consent 
(23; 8.7%), were pregnant or breastfeeding (11; 4.2%), were children (10; 3.8%), or had an alternative confirmed diagnosis before being approached for consent (8; 3.0%); 
6 patients (2.3%) were excluded for unrecorded reasons, and 3 (1.1%) withdrew from the study. The confirmed totals included those without culture or polymerase chain 
reaction evidence of dual pathogens.
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with 34 (24–58) hours for the D7 and 36 (24–51) hours for the 
D3 group (P = .002) (Table 4 and Figures 3–5).
The time-temperature AUC and FCT were also significantly 
larger and  longer, respectively, for patients in the A3 group 
with PCR-confirmed R. typhi (P = .02). Kaplan-Meier analysis 
demonstrated longer FCT for the A3 than for the D7 and D3 
groups (Figures 3–5; log-rank P < .02 for all diagnostic groups). 
There were no significant differences between D3 and D7 
groups for any of the outcomes (all P ≥ .20) and no significance 
difference in the risk of failure between younger (≤40 years) and 
older (>40 years) patients (P =  .11). Of the 103 patients with 
adverse event data at Mahosot Hospital, 59 (57%) had mild 
adverse events, excluding headache, which was a consistent fea-
ture of murine typhus (rash occurred in 15 of 93 [16.1%], diar-
rhea in 14 of 84 [16.7%], vomiting in 12 of 89 [13.5%]), with no 
significant difference between the 3 treatment groups (P = .06).
The median (IQR, range) duration of follow-up was 208 days 
(IQR, 165–369  days; range, 2–666  days) with 99 (55%) of the 
Mahosot Hospital patients completing 1 year. Twenty-six patients 
(12.0%) returned with fever (Supplementary Material); none were 
thought clinically to have murine typhus relapse. Of 14 patients 
with repeated R.  typhi PCR performed on readmission buffy 
coats all were negative. All returning patients recovered without 
antirickettsial antibiotic therapy and were well at discharge.
DISCUSSION
The results of this trial suggest that azithromycin is inferior to 
doxycycline as oral therapy for uncomplicated murine typhus. 
The clinical outcome measures of FCT, AUC, and frequency of 
treatment failure were significantly and consistently inferior for 
the azithromycin group compared with the doxycycline groups. 
Although the D3 group had longer FCTs, higher treatment fail-
ure frequency, and larger AUC than the D7 group, there were no 
significant differences (P ≥ .05) (Table 4), suggesting that 3 days 
of doxycycline is adequate for treating uncomplicated murine 
typhus in Lao adults. Owing to our limited understanding of 
the geographic  genomic, antimicrobial resistance variability 
of and human susceptibility to R. typhi, this conclusion can be 
generalized only with caution. These data have implications for 
the use of azithromycin in the empirical treatment of fever in 
communities where murine typhus is common [22].
There have been concerns that murine typhus may relapse, 
especially after early brief chloramphenicol therapy [23, 24], 
perhaps because of treatment discontinuation before develop-
ment of an effective immune response. In Laos we found no 
evidence of relapse, but active, rather than passive, long-term 
patient follow-up is required. Epidemic typhus is known to 
relapse, as Brill-Zinsser disease, but the interval between an ini-
tial attack of epidemic typhus and relapse is measured in years 
and not months [25].
Limitations of the current trial include the fact that we did 
not assay the quality of the study antibiotics before or during 
the trial, but they were manufactured by a major innovative 
pharmaceutical company and stored appropriately. We did not 
follow up patients actively after discharge. Even though murine 
typhus is a global disease, diagnostics have been neglected 
and are inadequate. There is no consensus on appropriate IFA 
murine typhus diagnostic cutoff titers for different levels of 
endemicity. Patients usually present with low R. typhi bacterial 
blood loads, and there has been minimal research on improve-
ments in diagnostic assays [26].
We chose an azithromycin dose of 500  mg followed by 
250 mg once a day for 2 days, based on evidence available for 
scrub typhus [27, 28]. A  randomized trial in Korean patients 
with scrub typhus found that a single 500-mg azithromycin 
dose was as efficacious, in terms of fever clearance and relapse, 
as doxycycline at 200 mg/d for 7 days [28]. To our knowledge, 
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Figure 2. Monthly recruitment of patients by admission month. Abbreviations: 
Aug, August; Dec, December; Feb, February; Jan, January; Nov, November; Oct, 
October; Sep, September.
Table  2. Pathogen Identification for the 175 Patients of 216 With 
Laboratory Diagnoses, Recruited to a Murine Typhus Clinical Trial
Pathogen
Patients, No.
Total Culture PCR Serology
Rickettsia typhi 158a,b NA 53a 155b
Orientia tsutsugamushi 7 NA 6 4
Salmonella enterica Typhic 5 5 NA NA
Leptospira spp. 4 NA 4a NA
Escherichia colic 1 1 NA NA
Salmonella enterica Paratyphi Ac 1 1 NA NA
Abbreviations: NA, not applicable; PCR, polymerase chain reaction.
aOne patient was PCR positive for both R. typhi and Leptospira sp. 
bA total of 160 patients had serologic evidence of R. typhi infection, but 5 had PCR/culture 
evidence of another pathogen (E. coli, Salmonella Typhi, and Leptospira sp. in 1 each and 
O. tsutsugamushi in 2). They may have had concurrent dual infections, but we have opted 
to be conservative and not included these 5 patients, giving a denominator of 155 patients.
cBlood culture and bacterial identification as described by Phetsouvanh et al [21].
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Table 3. Details of Patients Recruited to the 3 Treatment Groupsa
Variable Doxycycline (7 d) (n = 72) Doxycycline (3 d) (n = 72) Azithromycin (3 d) (n = 72) All Patients (n = 216)
Clinical and laboratory features
 Age, median (IQR), y 28.5 (21–43) 29.0 (21–40) 31.5 (24–42) 30 (22–41)
 Female sex, No. (%) 33 (45.8) 30 (41.7) 28 (38.9) 91 (42.1)
 Duration of illness, median (IQR), d 8 (7–10) 9 (7–10) 8 (7–10) 8 (7–10)
 Fever ≥37.5°C at admission, No. (%) 61 (84.7) 64 (88.9) 68 (94.4) 193 (89.4)
 Admission tympanic temperature, 
mean (95% CI), °C
38.6 (38.3–38.8) 38.4 (38.2–38.6) 38.6 (38.4–38.8) 38.5 (38.4–38.7)
 PCR- or serology-confirmed Rickettsia 
typhi , No. (%)b
55 (76.4) 54 (75.0) 49 (68.1) 158 (73.2)
 Serology-confirmed R. typhi, No. (%) 53/70c (75.7) 56/72 (77.8) 51/70 (72.9) 160/212 (75.5) 
 PCR-confirmed R. typhi, No. (%)b 20/71 (28.2) 18/69 (26.1) 15/71 (21.1) 53/211 (25.1)
 No PCR or serologic evidence of 
R. typhi, No. (%)
17 (23.6) 18 (25.0) 23 (31.9) 58 (26.9)
 R. typhi bacteremia, median (IQR), 
copies/μL whole blood 
3 (2–6) (n = 17)c 3 (2–4) (n = 15) 3 (2–4) (n = 13) 3 (2–6) (n = 45)
 PCR- or serology-confirmed O. tsutsu-
gamushi, No. (%)
0/69 5/69 (7.3) 2/69 (2.9) 7/207 (3.4)
  PCR-confirmed O. tsutsugamushi, 
No. (%)
0/71 4/69 (5.8) 2/71 (2.8) 6/211 (2.8)
 Other confirmed diagnoses, No. (%) 6/72 (8.3) 2/72 (2.8) 3/72 (4.2) 11/216 (5.1)
 No diagnosis made, No. (%) 12/72 (16.7) 11/72 (15.3) 18/72 (25.0) 41/216 (19.0)
 CRP, median (IQR), mg/L 40.8 (22.8–94.5) 
(n = 66)c
34.2 (14.0–95.2) 
(n = 63)
35.7 (19.0–59.4) 
(n = 68)
37.6 (18.5–83.3) 
(n = 197)
Antibiotic dosages
 Total doxycycline doses administered, 
median (range), No.d
15 (2–17) 7 (4–21) 0 (0–15) …
 Total duration of doxycycline treat-
ment, median (range), dd
7 (1–8) 3.5 (2–10) 0 (0–7) …
 Doxycycline dosage, mean (95% CI), 
mg/kg body weight dose per 100-mg 
dose
1.83 (1.75–1.92) 1.83 (1.76- 1.91) 1.84 (1.77–1.92) (n = 14)c …
 Total doxycycline dose, mean (95% 
CI), mg/kg body weightd
27.5 (26.0–29.0) 14.0 (13.1–15.0) 4.5 (2.3–6.7) …
 Total azithromycin doses administered, 
median (range), No.
0 0 4 (4–4) …
 Total duration of azithromycin treat-
ment, median (range), d 
0 0 3 (3–3) …
 Azithromycin dosage, mean (95% CI), 
mg/kg body weight dose per 250-mg 
dose
0 0 4.60 (4.42–4.79) …
 Total azithromycin dose, mean (95% 
CI), mg/kg body weight 
… … 18.9 (18.1–19.6) …
Outcome
 Patients withdrawing, No. (%) 1/72 (1.4) 1/72 (1.4) 1/72 (1.4) 3/216 (1.4)
 Patients vomiting loading dose within 
1 h, No. (%)
5/66 (7.6) 5/64 (7.8) 2/62 (3.2) 12/192 (6.3)
 Patients with mild adverse events, ex-
cluding headache, No. (%)e
26/36 (72) 17/37 (46) 16/30 (53) 59/103 (57)
 Duration of patient follow-up, median 
(range), d
190 (2–666) 319 (4–411) 224 (2–420) 208 (2–666)
 Patients returning with fever after ad-
mission, No. (%)
7 (9.7) 9 (12.5) 10 (13.9) 26 (12.0)
Abbreviations: CI, confidence interval; CRP, C-reactive protein; IQR, interquartile range; PCR, polymerase chain reaction.
aAntibiotic batch numbers were as follows: Vibramycin (Pfizer), 0658105B, 0558103B, 0758103C, 0558103D, 0558101C, and 0458102B; Zithromax (Pfizer), 914640271, 814360231, 
614646251, 616046261, 516645351, 714641322, 514645351, 214642178, 514665081, 014640091, and 516645351.
bWithout culture or PCR evidence of dual pathogens.
cDenominators are provided for variables with missing values.
dIncluding doxycycline given to those with treatment failure.
eMahosot Hospital patients only.
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no trials have compared different azithromycin dose regimens 
for any rickettsial disease.
These data have particular bearing for pregnant women 
with murine typhus [14]. It has been argued that doxycycline 
could be considered less stringently as therapy  in pregnancy 
and children, because no correlation was found between the 
use of doxycycline and teratogenic effects during pregnancy 
or dental staining in children [29]. However, recent evidence 
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Figure  4. Kaplan-Meier plot of fever clearance for patients with serology- or 
polymerase chain reaction (PCR)–confirmed murine typhus (n = 146).
Table 4. Outcome Measures in the Patients Recruited to a Murine Typhus Clinical Trial
Outcome Measure All Doxycycline (7 d) Doxycycline (3 d) Azithromycin (3 d) P Valuea
Treatment failure, No. (%)b
 All patients 20/213 (9.4) 1/71 (1.4) 3/71 (4.2) 16/71 (22.5) <.001
 PCR- or serology-confirmed 
Rickettsia typhi
11/157 (7.0) 0/54 2/54 (3.7) 9/49 (18.4) <.001
 PCR-confirmed R. typhi 7/51 (13.7) 0/18 1/18 (5.6) 6/15 (40.0) .002
 No PCR or confirmed sero-
logic evidence of R. typhi
9/56 (16.1) 1/17 (5.88) 1/17 (5.88) 7/22 (31.8) .06
Cleared fever, No. (%)c
 All patients 185/203 (91.1) 69/70 (98.6) 60/64 (93.8) 56/69 (81.2) <.001
 PCR- or serology-confirmed 
R. typhi
136/146 (93.2) 53/53 (100) 45/47 (95.7) 38/46 (82.6) <.001
 PCR-confirmed R. typhi 47/49 (95.9) 17/17 (100) 18/18 (100) 12/14 (85.7) .08
 No PCR or confirmed sero-
logic evidence of R. typhi
49/57 (86.0) 16/17 (94.1) 15/17 (88.2) 18/23 (78.3) .41
FCT, median (IQR), hc
 All patients 37 (24–66) 34 (24–58) 36 (24–51) 48 (24–96) .002
 PCR- or serology-confirmed 
R. typhi
36 (24–60) 32 (24–48) 36 (24–60) 43 (20–107) .02
 PCR-confirmed R. typhi 48 (30–66) 42 (30–60) 34 (24–60) 66 (48–162) .005
 No PCR or confirmed sero-
logic evidence of R. typhi
42 (24–78) 36 (24–68) 30 (24–50) 70 (24–100) .07
AUC,d median (IQR), °C * h 
 All 1368 (891–2259) 1243 (891–2016) 1312 (792–1923) 1639 (892–2648) .056
 PCR- or serology-confirmed 
R. typhi
1370 (895–2249) 1211 (903–1834) 1356 (681–2233) 1616 (743–2448) .26
 PCR-confirmed R. typhi 1827 (1130–2465) 1591 (1126–2247) 1312 (920–2267) 2360 (1827–4719) .02
 No PCR or confirmed sero-
logic evidence of R. typhi
1363 (891–2499) 1346 (455–2186) 1117 (911–1634) 1845 (892–3045) .20
Abbreviations: AUC, area under the time-temperature curve; FCT, fever clearance time; IQR, interquartile range; PCR, polymerase chain reaction.
aFrequencies were compared using χ2 tests across 3 groups (ie, 2 degrees of freedom), clearance times were compared using log-rank tests, and AUC estimates were compared using 
Kruskal-Wallis tests.
bTreatment failure was assessed in 213 patients; 3 patients withdrew, 1 in each arm, before treatment failure/success could be defined.
cOf 203 patients who presented with or developed fever, fever did not clear before discharge (or withdrawal) in 18; excluded are 12 patients who were afebrile at admission and 1 who 
withdrew at hour 0.
dAUC for period up to FCT or last patient follow up, if fever not cleared (excluding 12 patients with no fever at admission and 1 who withdrew at hour 0). AUCs for 4 patients afebrile at 
admission who developed fever during follow-up were calculated from the time of first temperature ≥37.5°C.
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Figure 3. Kaplan-Meier plot of fever clearance for all patients who presented 
with or developed fever (n = 203).
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has associated both doxycycline and azithromycin with spon-
taneous abortions [30].
Interestingly, 2 patients with Brill-Zinsser disease have been 
reported with failure of oral azithromycin therapy (500  mg/d 
for 3 days) [31]. Because R. typhi and R. prowazekii are closely 
related, these failures may have a similar mechanism to those 
we report. Acquired azithromycin resistance in other human 
pathogens, such as Mycoplasma pneumonia and Neisseria gon-
orrhoeae, is mediated by the ribosomal target of the antibiotic, 
23S ribosomal RNA [32]. We are aware of no equivalent data 
for R. typhi, and investigations of genomic (especially 23S ribo-
somal RNA) and phenotypic markers of resistance to azithro-
mycin, and 14-membered lactone ring macrolides, are urgently 
needed.
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